In a letter to Mandaviya recently, IDMA urged to consider stockpiling new drugs that are pending approval but have not yet been approved as such in the country. Such a provision would allow industry to meet requirements arising from any pandemic or other health emergency, he said.
The industry body asked the Ministry of Health and Family Welfare (MoHFW) to allow storage, as this would ensure that the right treatment would be available and could be used within a short time after receiving approval. of the drug.
âNeedless to say, drugs approved for storage would continue to go through the normal regulatory process and companies / agencies would only be allowed to offer such products for sale after they have been approved by drug regulatory agencies authorized in the country. the country. companies storing drugs at their own expense / risk for the benefit of patients would help save lives, âthe industry body said.
IDMA mentioned in the letter that one of the proactive government measures that helped India reach this milestone was the decision to stockpile vaccines.
The industry body further suggested that stockpiling should now be immediately considered for other (new) unapproved COVID-19 drugs that would keep India in a state of perpetual readiness for concerns the country’s pharmaceutical safety.
The industry body called on the minister to go one step further and consider stockpiling new drugs in general that are in the process of being approved in general but have not yet been approved as such in the country. Such a provision would allow drug manufacturers to cope with the demands arising from any pandemic or other health emergency, he added.